Form 4: Upstream Bio Director Harold Fleming Granted Stock Options, Disclaims Personal Beneficial Ownership for Enavate Sciences

Upstream Bio, Inc. director Harold Edward Fleming was granted 17,096 stock options with an exercise price of $11.59, but disclaimed personal beneficial ownership, holding them for the benefit of Enavate Sciences, LP.

Summary

• Harold Edward Fleming, a Director of Upstream Bio, Inc. (UPB), was granted 17,096 stock options on June 10, 2025.
• The stock options have an exercise price of $11.59 per share and an expiration date of June 9, 2035.
• The shares underlying these options will vest upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Mr. Fleming's continued service.
• Mr. Fleming has agreed to receive and hold these securities for the benefit of Enavate Sciences, LP.
• Consequently, Mr. Fleming disclaims beneficial ownership of, and all right, title, and interest in, the option and the shares issuable upon its exercise.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing an insider stock option grant. While the disclaimer of beneficial ownership is notable, it does not inherently indicate a positive or negative outlook for the company's operations or financial health.

Positives

• The grant of stock options aligns the interests of the director (or the entity they represent) with the long-term performance of Upstream Bio, Inc.

Negatives

• Harold Edward Fleming disclaims personal beneficial ownership of the granted stock options, indicating they are held for the benefit of Enavate Sciences, LP, which means the director does not personally benefit from this compensation.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedule of the granted options.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common in the biotechnology or pharmaceutical industry for director compensation. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• Harold Edward Fleming, a director, has agreed to receive and hold securities granted for his service for the benefit of Enavate Sciences, LP, disclaiming personal beneficial ownership.

Stakeholder Impact

• Shareholders: This filing provides transparency regarding director compensation arrangements and beneficial ownership, which is standard for corporate governance.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction filing.

Next Steps

• The stock options are subject to vesting upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders of the Issuer, contingent on continued service.

Key Dates

Keywords

Upstream Bio, UPB, Form 4, stock option, insider transaction, director compensation, beneficial ownership, Enavate Sciences